SCHEMBL17969185

SCHEMBL17969185

N#Cc1nn[nH]c1-c1ccc(/C=C/c2cccc(Cl)c2)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAOB P27338 5/20 0.43
▸ RELA Q04206 1/20 0.42
▸ MAOA P21397 2/20 0.40
▸ CHAT P28329 1/20 0.40
▸ GFER P55789 2/20 0.36
▸ GAA P10253 2/20 0.36
▸ MAPT P10636 2/20 0.36
▸ NPC1 O15118 1/20 0.36
▸ ALDH1A1 P00352 1/20 0.36
▸ LMNA P02545 1/20 0.36
▸ RAB9A P51151 1/20 0.36
▸ SMN1; SMN2 Q16637 1/20 0.36
▸ GRM5 P41594 2/20 0.35
▸ CYP1A2 P05177 2/20 0.35
▸ CYP2C9 P11712 1/20 0.35
▸ AKR1C3 P42330 1/20 0.35
▸ ALOX15 P16050 1/20 0.35
▸ CYP1A1 P04798 1/20 0.34
▸ CYP2D6 P10635 1/20 0.34
▸ CYP1B1 Q16678 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16399098 1.00 MAOB (0.43) MAOBRELAMAOACHATGFER
SCHEMBL16400381 0.87 ERBB2 (0.42) MAOBGAAMAPTNPC1ALDH1A1
SCHEMBL17969010 0.87 ERBB2 (0.42) MAOBGAAMAPTNPC1ALDH1A1
SCHEMBL16399387 0.85 KDM4E (0.39) MAOBRELAMAOAGFERGAA
SCHEMBL16399388 0.85 KDM4E (0.39) MAOBRELAMAOAGFERGAA
SCHEMBL17969114 0.81 ERBB2 (0.37) GAAMAPTNPC1ALDH1A1RAB9A
SCHEMBL17969113 0.81 ERBB2 (0.37) GAAMAPTNPC1ALDH1A1RAB9A
SCHEMBL16399601 0.81 CYP11B1 (0.36) MAOBMAOAMAPTNPC1ALDH1A1
SCHEMBL16399600 0.81 CYP11B1 (0.36) MAOBMAOAMAPTNPC1ALDH1A1
SCHEMBL16402513 0.80 NFE2L2 (0.44) MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4570313-A2 CYANOTRIAZOLE COMPOUNDS Otsuka Pharmaceutical Co., Ltd. (JP) 2025-06-18 — — EP claimed
EP-4219477-A1 CYANOTRIAZOLE COMPOUNDS Otsuka Pharmaceutical Co., Ltd. (JP) 2023-08-02 — — EP claimed
US-10626095-B2 Cyanotriazole compounds OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2020-04-21 — — US claimed
US-20160229816-A1 CYANOTRIAZOLE COMPOUNDS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2016-08-11 — — US claimed
EP-4570313-A2 CYANOTRIAZOLE COMPOUNDS Otsuka Pharmaceutical Co., Ltd. (JP) 2025-06-18 — — EP disclosed
EP-4219477-A1 CYANOTRIAZOLE COMPOUNDS Otsuka Pharmaceutical Co., Ltd. (JP) 2023-08-02 — — EP disclosed
US-10626095-B2 Cyanotriazole compounds OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2020-04-21 — — US disclosed
US-20160229816-A1 CYANOTRIAZOLE COMPOUNDS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2016-08-11 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10626095-B2 Cyanotriazole compounds CS, PC, ACAT1 MAOB 3664/4885RELA 1030/4885MAOA 4309/4885
US-20160229816-A1 CYANOTRIAZOLE COMPOUNDS CS, PC, ACAT1 MAOB 3664/4885RELA 1030/4885MAOA 4309/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback